SGH
CLDX icon

Schonfeld Group Holdings’s Celldex Therapeutics CLDX Stock Holding History

Schonfeld Group Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,631
Closed -$432K – 84
2014
Q1 		$432K Buy
+1,631
New +$625K 0.11% 279

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Schonfeld Group Holdings's CLDX Position: Q2 2014 in Review

Schonfeld Group Holdings sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 1,631 shares — an estimated $432K sold.

Schonfeld Group Holdings first reported a position in CLDX in Q1 2014 and held it in 1 quarter. The position peaked at $432K in Q1 2014. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • Schonfeld Group Holdings reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Schonfeld Group Holdings sold 1,631 Celldex Therapeutics shares in Q2 2014, an estimated $432K.
  • Schonfeld Group Holdings first reported a position in Celldex Therapeutics in Q1 2014 and held it in 1 quarter.
  • Schonfeld Group Holdings's Celldex Therapeutics position peaked at $432K in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on Schonfeld Group Holdings's 13F filing for Q2 2014, filed 15 Aug 2014.